Laurence Kraus‐Berthier

2.0k citations

50 papers · 1.4k indexed · h-index 24

Co-authors: Stéphane Léonce Alain St. Pierre Ghanem Atassi Nicolas Guilbaud Sylvie Michel Bruno Pfeiffer Michel Koch Pierre Renard
Topics: Cancer therapeutics and mechanisms (27 papers)Bioactive Compounds and Antitumor Agents (10 papers)Histone Deacetylase Inhibitors Research (7 papers)
Cited by: Toxicology Organic Chemistry Cancer Research
Journals: Blood PLoS ONE Cancer Research
Partner nations: France Belgium Australia

In The Last Decade

Laurence Kraus‐Berthier

50 papers receiving 1.3k citations

Peers

Countries citing papers authored by Laurence Kraus‐Berthier

Since Specialization

Citations

This map shows the geographic impact of Laurence Kraus‐Berthier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurence Kraus‐Berthier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurence Kraus‐Berthier more than expected).

Fields of papers citing papers by Laurence Kraus‐Berthier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laurence Kraus‐Berthier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurence Kraus‐Berthier. The network helps show where Laurence Kraus‐Berthier may publish in the future.

Co-authorship network of co-authors of Laurence Kraus‐Berthier

This figure shows the co-authorship network connecting the top 25 collaborators of Laurence Kraus‐Berthier. A scholar is included among the top collaborators of Laurence Kraus‐Berthier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laurence Kraus‐Berthier. Laurence Kraus‐Berthier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolation 2020 ·Investigational New Drugs ·(unknown),Émilie Hénin,Julien Ogier,(unknown),Laurence Kraus‐Berthier,Marylore Chenel,François Bouzom,Michel Tod	2
2	Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma 2019 ·Haematologica ·(unknown),(unknown),(unknown),Susana Hernández-García,Luís A. Corchete,Laura San‐Segundo,(unknown),(unknown),Marie Schoumacher,Sébastien Banquet,Laurence Kraus‐Berthier,Ioana Kloos,(unknown),Ensar Halilovic,Heiko Maacke,Norma C. Gutiérrez,María‐Victoria Mateos,Teresa Paíno,Mercedes Garayoa,Enrique M. Ocio	42
3	Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation Strategy 2019 ·Drug Metabolism and Disposition ·(unknown),Émilie Hénin,Kathryn Ball,Julien Ogier,(unknown),Laurence Kraus‐Berthier,Marylore Chenel,François Bouzom,Michel Tod	8
4	Combined BCL-2 and HDAC Targeting Has Potent and TP53 Independent Activity In AML 2018 ·Experimental Hematology ·Jessica M. Salmon,Giovanna Pomilio,Donia M. Moujalled,Sarah MacRaild,Charis E. Teh,Sewa Rijal,Adam Ivey,(unknown),Paul G. Ekert,Marie Schoumacher,Laurence Kraus‐Berthier,Ioana Kloos,Daniel H.D. Gray,Andrew H. Wei	2
5	Tumor Growth Inhibition Modelling Based on Receptor Occupancy and Biomarker Activity of a New Bcl-2 Inhibitor in Mice 2018 ·Journal of Pharmacology and Experimental Therapeutics ·(unknown),Émilie Hénin,Julien Ogier,Laurence Kraus‐Berthier,Marylore Chenel,François Bouzom,Michel Tod	3
6	Histone deacetylase inhibitor abexinostat affects chromatin organization and gene transcription in normal B cells and in mantle cell lymphoma 2016 ·Gene ·(unknown),Andrey Pichugin,Ana Barat,Valérie Camara‐Clayette,N. V. Vasilyeva,Hélène Lelièvre,Laurence Kraus‐Berthier,Stéphane Depil,Vincent Ribrag,Yegor Vassetzky	6
7	Targeting Bcl-2/Bcl-XL Induces Antitumor Activity in Uveal Melanoma Patient-Derived Xenografts 2014 ·PLoS ONE ·Fariba Némati,Catherine de Montrion,Guillaume Lang,Laurence Kraus‐Berthier,(unknown),Xavier Sastre‐Garau,(unknown),(unknown),Olivier Geneste,Ludmilla de Plater,Alain St. Pierre,Brian Lockhart,Laurence Desjardins,Sophie Piperno‐Neumann,Stéphane Depil,Didier Decaudin	37
8	The Histone Deacetylase Inhibitor Abexinostat Induces Cancer Stem Cells Differentiation in Breast Cancer with Low Xist Expression 2013 ·Clinical Cancer Research ·(unknown),Julien Wicinski,Olivier Cabaud,Yves Toiron,Pascal Finetti,Emmanuelle Josselin,Hélène Lelièvre,Laurence Kraus‐Berthier,Stéphane Depil,François Bertucci,Yves Collette,Daniel Birnbaum,Emmanuelle Charafe‐Jauffret,Christophe Ginestier	113
9	Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms 2013 ·Cell Death and Disease ·(unknown),Olivier Bluteau,Kahia Messaoudi,(unknown),Siham Boukour,Larissa Lordier,Yann Lécluse,Philippe Rameau,Laurence Kraus‐Berthier,(unknown),Hervé Lelièvre,Stéphane Depil,Philippe Dessen,Éric Solary,Hana Raslová,William Vainchenker,Isabelle Plo,Najet Debili	28
10	Influence of the Stereoisomeric Position of the Reactive Acetate Groups of the Benzo[b]Acronycine derivative S23906-1 on Its DNA Alkylation, Helix-Opening, Cytotoxic, and Antitumor Activities 2009 ·Molecular Pharmacology ·Sabine Depauw,Thomas Gaslonde,Stéphane Léonce,Laurence Kraus‐Berthier,William Laine,Gaëlle Lenglet,A. Chiaroni,Bruno Pfeiffer,Christian Bailly,Sylvie Michel,François Tillequin,Alain St. Pierre,Marie‐Hélène David‐Cordonnier	8
11	Novel Stable Camptothecin Derivatives Replacing the E-Ring Lactone by a Ketone Function Are Potent Inhibitors of Topoisomerase I and Promising Antitumor Drugs 2007 ·Molecular Pharmacology ·Amélie Lansiaux,Stéphane Léonce,Laurence Kraus‐Berthier,Christine Bal-Mahieu,(unknown),Sébastien Didier,Marie‐Hélène David‐Cordonnier,(unknown),Gilbert Lavielle,Christian Bailly,John A. Hickman,Alain St. Pierre	25
12	Cytotoxic and antitumoral properties in a series of new, ring D modified, olivacine analogues 2004 ·Bioorganic & Medicinal Chemistry ·(unknown),(unknown),Eric Raimbaud,Stéphane Léonce,Laurence Kraus‐Berthier,Alain St. Pierre,Solo Goldstein	22
13	Antitumor activity of S 16020-2 in two orthotopic models of lung cancer 1997 ·Anti-Cancer Drugs ·Nicolas Guilbaud,Laurence Kraus‐Berthier,(unknown),(unknown),(unknown),Mike F. Burbridge,(unknown),Ghanem Atassi	16
14	Experimental Antitumour Activity of S 16020-2 in a Panel of Human Tumours 1997 ·European Journal of Cancer ·Laurence Kraus‐Berthier,Nicolas Guilbaud,(unknown),(unknown),(unknown),Mike F. Burbridge,Alain Pierré,Ghanem Atassi	14
15	Synthesis and Biological Evaluation of 6-(9-Hydroxy-5-methyl(and 5,6-Dimethyl)-6H-pyrido(4,3-b)carbazol-1-yl)picolinic Amides as New Olivacine Derivatives. 1996 ·Chemical and Pharmaceutical Bulletin ·(unknown),(unknown),Alain St. Pierre,Stéphane Léonce,Nicolas Guilbaud,Laurence Kraus‐Berthier,(unknown),Yves Rolland,Ghanem Atassi,Émile Bisagni	5
16	In vivo antitumor activity of S 16020-2, a new olivacine derivative 1996 ·Cancer Chemotherapy and Pharmacology ·Nicolas Guilbaud,Laurence Kraus‐Berthier,(unknown),(unknown),(unknown),Mike F. Burbridge,(unknown),Émile Bisagni,Pierre Alexandre Eric Djifaby Sombié,Ghanem Atassi	23
17	Synthesis and Evaluation of 9-Hydroxy-5-methyl- (and 5,6-dimethyl)-6H-pyrido[4,3-b]carbazole-1-N-[(dialkylamino)alkyl]carboxamides, a New Promising Series of Antitumor Olivacine Derivatives 1994 ·Journal of Medicinal Chemistry ·(unknown),(unknown),Pierre Alexandre Eric Djifaby Sombié,Ghanem Atassi,Nicolas Guilbaud,Laurence Kraus‐Berthier,(unknown),Yves Rolland,Jacques Prost,Émile Bisagni	33
18	In vivo immunopharmacological properties of tuftsin and four analogs 1993 ·Immunopharmacology ·Laurence Kraus‐Berthier,G. REMOND,(unknown),(unknown),Bernard Portevin,Michel Vincent	3
19	New triazine derivatives as potent modulators of multidrug resistance 1992 ·Journal of Medicinal Chemistry ·(unknown),(unknown),(unknown),Alain St. Pierre,Stéphane Léonce,Laurence Kraus‐Berthier,(unknown)	58
20	Approaches to some biochemical mechanisms of action of tuftsin and analogues 1991 ·Biochemical Pharmacology ·Laurence Kraus‐Berthier,Gilles Ferry,(unknown),(unknown),G. REMOND,M. Vincent,Jean A. Boutin	7

About Laurence Kraus‐Berthier

Laurence Kraus‐Berthier is a scholar working on Toxicology, Oncology and Molecular Biology, having authored 50 papers that have together received 1.4k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (27 papers), Bioactive Compounds and Antitumor Agents (10 papers) and Histone Deacetylase Inhibitors Research (7 papers). The work is most often cited by research in Toxicology (153 citations), Organic Chemistry (531 citations) and Cancer Research (209 citations). Laurence Kraus‐Berthier has collaborated with scholars based in France, Belgium and Australia. Frequent co-authors include Stéphane Léonce, Alain St. Pierre, Ghanem Atassi, Nicolas Guilbaud, Sylvie Michel, Bruno Pfeiffer, Michel Koch, Pierre Renard, François Tillequin and Stéphane Depil. Their work appears in journals such as Blood, PLoS ONE and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact